Sage Journals: Discover world-class research

Abstract

Clozapine, a dibenzodiazepine developed in 1961, is a multireceptorial atypical antipsychotic approved for the treatment of resistant schizophrenia. Since its introduction, it has remained the drug of choice in treatment-resistant schizophrenia, despite a wide range of adverse effects, as it is a very effective drug in everyday clinical practice. However, clozapine is not considered as a top-of-the-line treatment because it may often be difficult for some patients to tolerate as some adverse effects can be particularly bothersome (i.e. sedation, weight gain, sialorrhea etc.) and it has some other potentially dangerous and life-threatening side effects (i.e. myocarditis, seizures, agranulocytosis or granulocytopenia, gastrointestinal hypomotility etc.). As poor treatment adherence in patients with resistant schizophrenia may increase the risk of a psychotic relapse, which may further lead to impaired social and cognitive functioning, psychiatric hospitalizations and increased treatment costs, clozapine adverse effects are a common reason for discontinuing this medication. Therefore, every effort should be made to monitor and minimize these adverse effects in order to improve their early detection and management. The aim of this paper is to briefly summarize and provide an update on major clozapine adverse effects, especially focusing on those that are severe and potentially life threatening, even if most of the latter are relatively uncommon.

Keywords

adverse effects clozapine life threatening management resistant schizophrenia

Introduction

Schizophrenia is a chronic and debilitating disease affecting approximately 0.5% of the population.¹ Antipsychotics are the mainstay of treatment of such a severe disorder, but it has been widely demonstrated that between 20% and 60% of patients with schizophrenia do not respond sufficiently to conventional treatments.²

Clozapine, a dibenzodiazepine developed in 1961, is a multireceptorial atypical antipsychotic approved for the treatment of resistant schizophrenia.³ Since the pivotal study of Kane and colleagues⁴ it has remained the drug of choice in treatment-resistant schizophrenia despite a wide range of adverse effects.⁵ It has been demonstrated that clozapine is more effective than any other first-generation (FGA) or second-generation antipsychotics (SGA) in the treatment of resistant schizophrenia and it is also useful in other conditions^6,7 (Table 1). It has been estimated that almost two thirds of those patients who do not respond adequately to treatment with FGAs or other SGAs may respond adequately to treatment with clozapine.⁸ Undoubtedly, clozapine is a very effective drug in everyday clinical practice and many patients who tolerate it will experience remarkable symptom relief that is often protracted in time and gives them the opportunity to achieve a satisfactory quality of life.⁹

Table 1.

Benefits of clozapine use in clinical practice (modified from De Berardis et al.¹⁰)

Established effectiveness in treatment-resistant schizophrenia, both in the short and the long term

Effective on both positive and negative symptoms of treatment-resistant schizophrenia

Effective in improving patients’ functioning and quality of life in treatment-resistant schizophrenia

Effective in reducing aggressive behavior, hostility and excitement in schizophrenia

Effective in reducing the comorbid use of alcohol and drugs in patients with schizophrenia, possibly by a reduction in craving

Effective in reducing suicidality in schizophrenia

Efficacious in severe and treatment-resistant mood disorders

Efficacious in drug-induced psychosis in Parkinson’s disease, without worsening Parkinsonism

Effective in reducing drug-induced tardive dyskinesia

Clozapine treatment may decrease mortality from natural or disease-related causes in treatment-resistant schizophrenia

However, clozapine is not considered as a first-line treatment because it may often be difficult for some patients to tolerate, as some adverse effects may be particularly bothersome (i.e. sedation, weight gain, sialorrhea etc.) and some others are potentially dangerous and life threatening.¹¹ Specifically, the risk of agranulocytosis is one of the main reasons why clozapine is not a first-line agent for schizophrenia.¹²

Moreover, clozapine may have several interactions with other drugs as it is metabolized by the hepatic cytochrome P450 (CYP) system.¹³ Clozapine is transformed to norclozapine by CYP3A4 and 1A2 and to clozapine N-oxide by CYP3A4.¹⁴ Nevertheless, CYP2C19 is also significant at clozapine therapeutic concentration (24%) while the influences of CYP2C9 (12%) and 2D6 (6%) are more modest.¹⁵ CYP1A2 is the most significant form at a therapeutic concentration (30%), while CYP3A4 plays an important role at higher concentrations (37%) than at therapeutic concentrations (22%).^16,17 All considered, blood-level monitoring of clozapine may be needed both when inhibitors (such as antifungals, oral contraceptives, fluvoxamine, ciprofloxacin, caffeine, disulfiram) or inducers (such as rifampicin, omeprazole, phenytoin, phenobarbital, tobacco smoke) of CYP1A2 and both inhibitors (such as cimetidine, erythromycin, clarithromycin etc.) or inducers (such as carbamazepine and rifampicin) of CYP13A4 are being used.¹⁸ It is important to note that tobacco smoking may affect clozapine metabolism through CYP1A2 induction, thus resulting in lower clozapine levels in smokers. This may cause adverse effects if a patient under clozapine treatment quits smoking because clozapine blood levels may rise up to 50–70%, potentially leading to toxic concentrations and development of adverse effects.¹⁹

Therefore, it is important to conduct careful therapeutic drug monitoring (TDM) for any patient on clozapine. As reported by Bastiampillai and colleagues,²⁰ clozapine blood levels should usually be evaluated at least a week after a stable clozapine dose has been reached as a trough level. There is evidence that clozapine levels above 600 μg/ml may increase the risk of seizures, and prophylactic antiepileptics should be considered.²¹ Clozapine serum-level monitoring may also be useful to evaluate clinical efficacy, in addition to checking for side effects and toxicity, with levels between 350 and 400 μg/ml significantly associated with improved clinical response rates, but also with a significantly increased side-effect burden.^21–23

As poor treatment adherence in patients with resistant schizophrenia may increase the risk of psychotic relapse,²⁴ which may further lead to impaired social and cognitive functioning, psychiatric hospitalizations, suicide risks and increased treatment costs,^25,26 clozapine adverse effects are a common reason for discontinuing this medication and this is a cause of concern.^27,28 Therefore, all efforts should be made to monitor and minimize adverse effects, improve their early detection and conduct proper management, also to reduce the risk of people being harmed.²⁹ This must be done considering that, when clozapine fails, there are no effective therapeutic strategies that can be put in place.³⁰

The aim of this narrative review is to briefly summarize and provide an update on major clozapine adverse effects, especially focusing on those that are severe and potentially life threatening, even if most of the latter are relatively uncommon. Adverse reactions were divided by frequency regarding patients and treatment: common (⩾1/100), uncommon (⩾1/1000) and rare (⩾1/10,000) (see Table 2).

Table 2.

Adverse effects of clozapine (in brackets potentially life-threatening adverse effects if not recognized early, LT). Adverse reactions were divided by frequency regarding patients and treatment: common (⩾1/100), uncommon (⩾1/1000) and rare (⩾1/10,000).

Common	Uncommon	Rare
Sedation	Agranulocytosis (LT)	Myocarditis/pericarditis (LT)
Hypertension	Diabetes mellitus/hyperglycemia/DKA (LT)	Cardiomyopathy (LT)
Weight gain	Metabolic syndrome	Heat stroke (LT)
Seizures (LT)	Delirium	Hepatic failure (LT)
Hypersalivation or sialorrhea	Liver enzyme abnormalities	Colitis (LT)
Benign fever	Interstitial nephritis	Intestinal obstruction/paralytic ileus (LT)
Hypotension	Stuttering	Pancreatitis (LT)
Nausea	Thrombocytopenia	Pneumonia (LT)
Nocturnal enuresis	Dysphonia	Respiratory failure (LT)
Gastroesophageal reflux	Neuroleptic malignant syndrome (LT)	Vasculitis
Constipation		Skin rash
Tachycardia		Ocular pigmentation
Dizziness		Priapism
Blurred vision		Parotid gland swelling
Dysarthria		Rhabdomyolysis
Blood dyscrasias such as leukopenia/decreased WBC/neutropenia/eosinophilia/leukocytosis		QT prolongation (LT)
		Sudden death (LT)

DKA, diabetic ketoacidosis; WBC, white blood cell.

Materials and methods of the review

Searches of the Medline database from 1980 to December 2017 and the PsycInfo/Embase database from 1980 to December 2017 were conducted and restricted to the English language. The search term ‘clozapine’ was combined with ‘adverse effects’, ‘side effects’ and ‘toxicity’ to identify relevant original research and review articles. All citations were screened and the full texts of peer-reviewed journal articles that were considered relevant for the purposes of the review were obtained. Bibliographies were scanned to locate additional relevant publications, even those prior to 1980. However, this paper is a narrative review. This type of review is useful when the aggregation of data is difficult because different studies or fields are being analyzed, but the methodology is less strict than in a systematic review.

Clozapine mechanism of action and relationships with adverse effects

Clozapine is a multireceptorial atypical antipsychotic approved for the treatment of resistant schizophrenia.³¹ Concerning DA receptors, clozapine has a higher affinity for D1 and D4 than D2 receptors.³² Moreover, clozapine is characterized by a rapid dissociation from D2 receptors (the ‘fast off’ phenomenon), which accounts for a more robust antipsychotic effect and a lower propensity to cause extrapyramidal symptoms and hyperprolactinemia.^33,34

Clozapine has an affinity for several other receptors, including serotonergic 5-HT1A, 5-HT1C, 5-HT2A, 5-HT2C,5-HT3, 5-HT6, 5-HT7 receptors, adrenergic α1 and α2 receptors, histaminergic H1, H3, H4 receptors, and muscarinic M1 and M5 receptors.³⁵ These affinities, especially for adrenergic, histaminergic and muscarinic receptors, may explain some adverse effects commonly seen during clozapine administration, whereas some other adverse effects do not necessarily depend on clozapine-related receptor agonism or antagonism.²⁰

Furthermore, some populations, that is the elderly or adolescents, may be particularly vulnerable to clozapine adverse effects despite its proven efficacy.^36–38

Besides clozapine activity on brain neurotransmitters and their receptors, a potential immune-mediated mechanism of action has been suggested.^39,40 Clozapine may influence the cytokine system, especially during the first months of treatment, by increasing proinflammatory cytokines and C-reactive protein (CRP), and acting as an immunomodulatory drug in some circumstances.^41–44 In fact, both in vitro and in vivo studies confirmed the immunomodulatory actions of clozapine.^45–49 These effects of clozapine on the immune system may account for its efficacy in the treatment of schizophrenia in accordance with an immunological hypothesis of disorder etiology,^50,51 but also for some adverse effects (i.e. eosinophilia, benign hyperthermia, cardiovascular and hematological adverse effects etc.).^39,52

Common adverse effects

Orthostatic hypotension, often seen when initiating treatment, especially in the case of a rapid titration, and sexual dysfunction are mostly related to adrenergic α blockade,^53–55 whereas sedation and constipation (see below for the latter) may be mainly due to H1 blockade.^56,57 Clozapine-induced orthostatic hypotension and sedation may increase the risk of falls, especially in the elderly.^36,58 Clozapine antagonism on muscarinic M1 receptors is responsible for anticholinergic effects such as constipation, tachycardia, blurred vision and urinary retention.⁵⁹ Other common adverse effects include dizziness, transient eosinophilia, sialorrhea, benign hyperthermia, leukocytosis and nausea.⁶⁰ Among the latter, sialorrhea may be particularly bothersome, although it is benign, dose related and often transient. However, there are some cases of aspiration pneumonia in patients treated with clozapine who have sialorrhea, so such an effect must be carefully evaluated.^61,62 The management of clozapine-related sialorrhea is often problematic, but some strategies have been tried with good results, such as a low-dose amisulpiride or amytriptiline, bupropion, sublingual atropine, scopolamine, trihexyphenydil and glycopyrrolate, with the latter shown to be the most effective.^63–67

Among the common adverse effects, the most dangerous and potentially life threatening are seizures and weight gain or metabolic syndrome (MetS).

Seizures

Seizures may be a relatively common and potentially life-threatening adverse effect of clozapine.⁶⁸ In fact, clozapine may lower the seizure threshold not only in individuals at risk of epilepsy, but also in apparently healthy subjects.⁶⁹ The seizure risk during clozapine treatment has been estimated at roughly 1–6%, is usually dose dependent and may appear more frequently in younger patients.^70,71 It has been reported that rapid titration and higher dosages of clozapine (⩾600 mg/day) were associated with greater risk than medium (300–600 mg/day) or low dosages (<300 mg/day).⁷²

Moreover, rapid clozapine titration may further increase seizure onset.⁷⁰ Even if a higher risk of seizures during clozapine titration has been reported, this adverse effect may appear during all phases of treatment, even after several years of therapy.⁷³ Patients who develop seizures during clozapine titration or maintenance treatment may continue clozapine with dose reduction, or better still, the addition of an antiepileptic medication. Valproate may be the best choice, even if this combination must be carefully monitored.^74,75 Electroencephalography and clozapine plasma blood-level monitoring are recommended to avoid or minimize seizure risk.^76,77

Weight gain and the risk of MetS

Second-generation antipsychotics are generally associated with weight gain, particularly olanzapine and clozapine, and with related risks of metabolic disturbances such as insulin resistance, type 2 diabetes, dyslipidemia and diabetic ketoacidosis (DKA).⁷⁸

Weight gain is a common adverse effect of clozapine that, per se, may be not potentially life threatening if properly managed and treated.⁷⁷ If not, the consequent development of MetS may be a major health concern which highly increases the risk of developing type 2 diabetes mellitus and cardiovascular diseases.^79,80 A relationship between weight gain and clozapine doses has been proposed, but this point remains controversial.⁸¹

Clozapine metabolic abnormalities are mostly linked to 5-HT2A and 5-HT2C receptor blockade, but the effects on histaminergic and adrenergic receptors are also thought to play a significant role.^82–84

Even if the prevalence of MetS in patients with schizophrenia is higher compared with the general population, going up to 40%, the effect of clozapine is remarkable with a prevalence rate varying from 11% to 64% among treated patients.^85,86 Allison and colleagues reported that clozapine treatment was associated with an average gain of 9.8 lb over 10 weeks and this was the highest figure of all antipsychotics.⁸⁷ The incidence of clozapine-related weight gain is considered to be the most significant at 5–35%, and almost half of patients may gain 20% or more of their initial body weight, especially if they are on polypharmacy, have a sedentary lifestyle or are not overweight at baseline.⁸⁸ Several studies have also associated clozapine treatment with the development of dyslipidemia and hypertension,^77,89–91 all factors that may affect MetS or make it worse. The metabolic risk associated with clozapine treatment may be increased in the short term after treatment initiation. In fact, it has been demonstrated that the increased short-term metabolic risk associated with clozapine may be diminished over time because multiple other variables are also likely to affect the metabolic risk during the lifespan.⁹²

Clozapine treatment may also be associated with diabetes and DKA.^93,94 Regarding DKA, Cohen and colleagues⁹⁵ found a 1-year incidence rate of 1.2–3.1% and a case fatality rate of 20–31%, making DKA one of the riskiest side effects, with higher mortality than agranulocytosis with an incidence of 3.8–8.0% and case fatality rate of 2.2–4.2%. Therefore, the authors proposed that the screening guidelines should be modified with an early detection of treatment-emergent hyperglycemia through an obligatory monthly measurement of fasting plasma glucose. It has also been demonstrated that clozapine-related DKA typically occurs early in the course of treatment, when clozapine treatment duration is short and doses are low.⁹⁶

Especially with combined behavioral interventions consisting of both nutritional counseling and diet modification), aripiprazole, topiramate, orlistat and metformin additions have been shown to be beneficial in reducing clozapine-induced weight loss, even if the evidence is based on a limited number of randomized controlled trials and further studies are needed.^88,97,98 Counseling for patients needing proper diet and exercise for weight and glucose control should always be recommended.⁹⁹

Gastrointestinal hypomotility and constipation

The anticholinergic peripheral properties of clozapine as well as its H1 antagonism properties were related to several grades of impairment of intestinal peristalsis ranging from transient to obstinate constipation and paralytic ileus up to intestinal obstruction.^100,101 It is known that even low or therapeutic doses of clozapine may prolong colonic transit time (CTT).¹⁰²

These effects are mainly mediated by the clozapine antagonism on cholinergic and serotoninergic receptors in the gut wall.¹⁰³ It has been demonstrated that clozapine, but not norclozapine, has potent effects on the motility of the colon of a rabbit, thus inhibiting neurogenic contractions at lower concentrations and myogenic contractions at higher concentrations.¹⁰⁴ These effects may be mediated by cholinergic and serotonergic receptors, presumably via M1–M3 and 5HT-3 and 5HT-7 receptors. Moreover, de Alvarenga and colleagues¹⁰⁵ showed that clozapine significantly reduced the frequency of cycles of contractions of zebrafish larvae gastrointestinal tracts through anticholinergic action.

These adverse effects are bothersome for several patients who develop mild constipation, which is often a treatment discontinuation cause, but it may become severe and potentially life threatening in some others who develop moderate to severe untreated constipation or even an adynamic ileus.¹⁰³ In fact, constipation is very frequent in patients treated with clozapine with an estimate range varying from 15% to 60% in accordance with several studies.^106,107 Moreover, Every-Palmer and Ellis¹⁰⁸ reviewed all reports of serious clozapine-induced gastrointestinal hypomotility (CIGH, also known as clozapine-related ‘slow gut’) submitted to the Australian Therapeutic Goods Administration and New Zealand Pharmacovigilance Centre between 1992 and 2013 and found that the reported prevalence of serious CIGH was 37/10,000, likely an underestimation of the true prevalence. CIGH is relatively common as between 50% and 80% of patients treated with clozapine have unambiguous objective evidence of CIGH in colonic transit studies,¹⁰² with mean transit times that are four times longer than normal, affecting all regions of the colon.¹⁰⁶ It is worth noting that studies which have relied on reporting of constipation are not very sensitive in diagnosing slow gut.

In fact, rare but potentially fatal clozapine-related adverse effects are intestinal obstructions and a paralytic ileus that occur in almost 2% of treated patients.¹⁰⁹ In severe cases, constipation progresses to ileus and bowel ischemia, with multiple fatalities related to aspiration of feculent vomit, sepsis and perforation, as described in the literature.¹¹⁰ Prolonged gastrointestinal hypomotility and constipation may promote ischemia, increasing intraluminal pressure and compression of mucosal vessels. As a consequence, bacterial translocation, inflammation and ischemia of the segment of bowel proximal to the obstruction will develop.^111–113 One case of clozapine-induced severe constipation leading to a silent presentation of pneumonia with a subsequent respiratory arrest¹¹⁴ has also been reported.

Clozapine-related ileus has been reported to be dose dependent and may occur several days after initiation of treatment as well as at any time during treatment, with the latter often triggered by concomitant medications known to affect the gastrointestinal system, especially those with anticholinergic properties.¹¹⁵ Therefore, early detection and treatment of constipation and ileus are mandatory to avoid fatalities.

The recommendation of an adequate intake of fluids, especially in the presence of hypersalivation, and regular physical activity is mandatory in such patients, as well as dose reduction or laxative prescriptions to avoid the progression of severe gastrointestinal adverse effects.^107,116,117 Recently, Every-Palmer and colleagues¹¹⁸ demonstrated that patients with clozapine-related constipation treated with docusate and senna augmented by macrogol had reduced CTTs and this was beneficial in treating constipation. Also, orlistat was found to be helpful,¹¹⁹ but further studies are needed.

Uncommon adverse effects

Less common adverse effects associated with clozapine treatment may include delirium, liver enzymes abnormalities, interstitial nephritis, stuttering, thrombocytopenia and dysphonia.¹²⁰

Moreover, several cases of clozapine-related neuroleptic malignant syndrome have been reported, often characterized by atypical features, that is, with less intense extrapyramidal symptoms or high fever.^121,122 However, it should be noted that the majority of published cases were reported in subjects with comorbid conditions¹²³ or under polypharmacy with different antipsychotics, especially those with higher affinity on dopamine D2 receptors, such as risperidone, amisulpride and olanzapine or other drugs.^124–126

Blood dyscrasias and agranulocytosis/granulocytopenia

Blood dyscrasias, such as mild to moderate leukopenia decreased white blood cell count, mild neutropenia, anemia, eosinophilia and leukocytosis, are often seen with clozapine but, if cautiously monitored, in the majority of the cases this may be transient or benign.^127,128

The most severe and potentially life-threatening clozapine-related blood dyscrasias is neutropenia, which may eventually develop into clozapine-induced agranulocytosis or granulocytopenia. This occurs in roughly 0.8–2% of patients and requires mandatory hematological monitoring.^20,129 The occurrence of agranulocytosis or granulocytopenia even led to the partial withdrawal of clozapine from the market and strong restrictions to its use in the mid 1970s.¹³⁰

Neutropenia was defined in the 2005 clozapine guidelines as an absolute neutrophil count (ANC) below 1500 and occurs in approximately 3% of treated patients,¹³¹ whereas agranulocytosis was defined as an ANC below 500/mm³.^132,133 A transient neutropenia (1 week) or weekly variations of ANC are relatively common during clozapine treatment and do not necessarily require treatment discontinuation, but it is not known why some patients develop transient neutropenia whereas others progress to having agranulocytosis.^134,135

Although the highest risk of agranulocytosis has been reported to occur during the first 12 weeks from clozapine titration and during the first 6 months of treatment, patients may develop severe blood dyscrasia anytime during the treatment, even if the risk decreases exponentially over time after the first 6 months of treatment.¹³⁵ However, some cases of late-onset clozapine-induced agranulocytosis have been reported.^136,137 The development of agranulocytosis may be independent of dosage and risk factors include older age, female sex, human leukocyte antigen haplotypes and concomitant treatment with other drugs known to cause agranulocytosis.^52,138–142 Interestingly, in cases with severe clozapine-induced agranulocytosis, the occurrence did not depend on the clozapine dosage.¹⁴³

To explain this dangerous adverse effect, several studies have hypothesized a potential interaction between clozapine and the immune system, suggesting an immune-mediated mechanism to be involved in its adverse effects or even in its clinical efficacy.^144,145 It is also possible that some subjects may be genetically predisposed; oxidative clozapine degradation may cause the development of some metabolites with reactive nitrenium ions, which may covalently bind to human leukocytes, resulting in direct toxicity or leading to the development of aptenic formation of an antigenic structure that will stimulate a targeted immune response.^146–148

The 2015 US Food and Drugs Administration guidelines for hematologic monitoring during clozapine therapy^149–151 recommend that treatment is not discontinued in the case of mild neutropenia (⩾1000–1499/mm³), with ANC monitored three times weekly until it is at least 1500/mm³. However, in the case of moderate neutropenia (⩾500–999/mm³), they recommend that treatment is interrupted when clozapine-induced neutropenia is suspected, with daily monitoring performed until ANC is at least 1000/mm³ (when treatment may resume), and consequently monitoring carried out three times weekly until ANC is at least 1500/mm³, then proceeding with weekly checks for 4 weeks, and finally returning to the patient’s last normal range ANC monitoring plan.

In the case of severe neutropenia (<500/mm³), all patients must interrupt treatment for suspected clozapine-induced neutropenia and clozapine rechallenge should not be considered unless the prescriber, along with a hematologist consultation, determines that the benefits outweigh the risks.¹⁵² Recently, some studies have pointed out that granulocyte colony-stimulating factor may be beneficial in the treatment of clozapine-induced agranulocytosis,¹⁵³ but more evidence is needed and withdrawing clozapine is still mandatory in such cases.

Clozapine rechallenge is always a risk after an episode of agranulocytosis as several reports observed a new episode of blood dyscrasia.^154,155 However, there are also some reports that observed no blood dyscrasia when clozapine was reintroduced after an episode of agranulocytosis with or without adjuvant therapies.^156–158 Dunk and colleagues¹⁵⁹ conducted clozapine rechallenge in 53 patients who developed leucopenia or neutropenia during previous clozapine treatment and found that 38% experienced a further blood dyscrasia whereas 55% did not. More recently, Prokopez and colleagues¹⁶⁰ analyzed the results of a clozapine rechallenge after leucopenia or neutropenia in 19 patients and observed that almost 70% of the patients did not develop a new hematological adverse effect, whereas the remaining 30% had a faster but less serious neutropenia. In conclusion, clozapine rechallenge requires careful evaluation and should be taken into consideration on a case-by-case basis when the risks outweigh the benefits for all other strategies.

Uncommon adverse effects

Clozapine may be associated with several uncommon adverse effects such as vasculitis, skin rash, ocular pigmentation, priapism, parotid gland swelling and rhabdomyolysis that may not always be severe but require cautious monitoring.⁵ However, some of the (fortunately) rare adverse effects may be severe and potentially life threatening, and these include heat stroke, hepatic failure, colitis, pancreatitis, pneumonia and respiratory failure.⁷

QT prolongation

It has been reported that clozapine may be associated with QT prolongation in a dose-dependent manner.^161,162 In most cases, drug-induced QT prolongation is not significant per se, whether it is symptomatic or malignant,¹⁶³ but in some individuals it may lead to the life-threatening torsades de pointes, a sudden and often fatal arrhythmia.¹⁶⁴

The effect on QTc is not peculiar to clozapine; it is often seen with other antipsychotics, especially FGAs, and other psychiatric drugs.^165–167 Almost all of the drugs known to prolong the QT interval both directly or through one of their metabolites seem to preferentially block the rapid component of the delayed rectifier outward K+ current, IKr, of an ion channel in ventricular cardiomyocytes, whose α subunit is encoded by the human ether-a-go-go related gene (HERG).¹⁶⁸

Clozapine has demonstrated the capability to block HERG currents and this may account for drug-induced QT prolongation.¹⁶⁹ However, it is known that clozapine may induce an increased heart rate and this may influence the QTc determination (when using Bazett’s formula), leading to an overestimation of this effect.¹⁷⁰

All considered, clozapine seems to rarely influence QT traits. However, electrocardiogram monitoring is always useful when clozapine is commenced or when administered together with other drugs, and in elderly patients.^171–175 The QT interval should be calculated using methods involving linear regression, adjusting for age and sex, as recommended by the American Heart Association,¹⁷⁶ and not with Bazett’s formula. Clozapine dose reductions may be useful for QT prolongation, especially in the case of polypharmacy.¹⁷⁷

Clozapine-induced cardiomyopathy, myocarditis and pericarditis

Clozapine may be associated with the occurrence of severe cardiovascular side effects, including dilated cardiomyopathy, myocarditis and pericarditis, which may be fatal when not timely recognized and managed.^10,170

Dilated cardiomyopathy is an uncommon, dose-independent, but potentially life-threatening adverse effect of clozapine treatment. It may occur even after a longer drug exposure and is often confused with myocarditis.¹⁷⁸ The clinical manifestations of clozapine-induced cardiomyopathy range from subclinical forms to severe ones with fulminant pulmonary edema and cardiogenic shock.^179,180 Often the symptoms are insidious and include persistent tachycardia at rest, palpitations, arrhythmias, dyspnea, chest pain, malaise and other signs and symptoms that may be underestimated by the clinicians until the symptoms resemble the clinical picture of heart failure or myocardial infarction.¹⁸¹

Myocarditis is an uncommon, dose-independent, life-threatening adverse effect and occurs in up to 3% of treated patients.^182,183 Moreover, several sudden deaths reported with clozapine use may be due to an unrecognized or fulminant myocarditis.¹⁸⁴ Although myocarditis has a tendency to appear at any time during treatment with clozapine, this has been reported more frequently from 4 days to 22 weeks after treatment initiation,¹⁸⁵ with a particular ‘danger period’ during the first 4 weeks following initiation.¹⁸⁶

The clinical presentation of clozapine-related myocarditis in adults may be highly variable, ranging from subclinical diseases to fulminant heart failure.^187,188 Flu-like symptoms such as fatigue, fever, myalgias, dizziness, arthralgias, nasal congestion and sensations of ‘scratchy throat’ may often be the first to appear and are sometimes unrecognized or underestimated.^189,190

Respiratory symptoms, such as dyspnea, cough, subjective sensations of chest discomfort and orthopnea, as well as cardiovascular symptoms, such as persistent resting tachycardia, increased heart rate, palpitations, chest pain, syncope, arrhythmias and hypotension, are the main symptoms that drive the diagnosis. However, in some cases, clozapine-related myocarditis may develop in an atypical form without accompanying symptoms and these cases are often fatal.^191,192

It has been suggested that risk factors for any cardiac complications of clozapine may be the rapid dose titration, the presence of weight gain or metabolic adverse effects, the coadministration of selective serotonin reuptake inhibitors and the use of illicit substances.^193–195 Moreover, concomitant treatment with medications that have been implicated as the cause of cardiovascular complications like myocarditis and heart failure, namely some antibacterials, cisapride, thyroxine, ranitidine, cyclophosphamide, lithium, phenotiazines and certain antidepressant agents like amytriptiline, imipramine and desipramine, may represent another risk factor when a patient is taking clozapine.¹⁹⁶ Interestingly, some cases of clozapine-related myocarditis were detected in patients taking valproate, which is often prescribed to prevent seizures or as a mood stabilizer.^184,195,197 Hence, when clozapine is administered together with valproate, patients should be more carefully and strictly evaluated for an eventual myocarditis onset.

The early detection of clozapine-related myocarditis is mandatory as early recognition improves clinical outcome and reduces mortality.^170,198 To date, the monitoring protocol adapted from De Berardis and colleagues¹⁰ and Ronaldson and colleagues¹⁸⁵ seems to be scientifically sound and clinically useful in everyday clinical practice (see Figure 1).

Figure 1.

Proposed protocol for monitoring patients commenced on clozapine for clozapine-related cardiomyopathy, myocarditis and pericarditis (adapted and modified from De Berardis et al.¹⁰ and Ronaldson et al.¹⁸⁵). ICU, intensive care unit; ULN, upper limit of normal.

When myocarditis is suspected or diagnosed, immediate clozapine cessation is mandatory as usually this may resolve the case within a few days or weeks.⁶⁰ However, some patients may require treatment with a β blocker or angiotensin-converting enzyme inhibitor, whereas severe cases will need mechanical ventilation.^199,200 Corticosteroids have been administered in some cases, but their efficacy is uncertain.^201,202

As far as clozapine rechallenge after an episode of myocarditis is concerned, it should be noted that this strategy may be dangerous, is not recommended, and should be employed after careful evaluation of the pros and cons together with a consultation with a cardiologist,^170,203,204 even though there are some positive reports.^{191,205–207}

Moreover, several cases of clozapine-related pericarditis have been reported in the literature in patients on stable clozapine regimens for several weeks, months or even years, or during the titration phase.^208–211 In the majority of published cases, clozapine treatment was immediately discontinued, resulting in complete resolution of symptoms.²¹² In some cases, clozapine rechallenge was tried, but this strategy is controversial as pericarditis may develop again, even though this is not the rule.^213,214

Venous thromboembolism

There are several reports on clozapine-related venous thromboembolism (VTE), but luckily it seems to be relatively rare and dose independent.^215–217 The mechanism of this dangerous adverse effect remains unknown.^218–220 Axelsson and colleagues²²¹ compared several antipsychotics and found that clozapine was the only compound that increased platelet adhesion and aggregation, and shortened activated partial thromboplastin time, even at therapeutic concentrations. Moreover, in a case report, clozapine induced an allergic vasculitis that resulted in VTE.²²²

Nevertheless, the risk of VTE seems to be an adverse effect of several antipsychotics including clozapine,^223,224 and may be higher in elderly patients and in women taking high doses or receiving parenteral antipsychotics.^225–228 However, it has been suggested that VTE may be more a consequence of several risk factors for VTE present in patients with psychiatric disorders, such as MetS, inactivity, low levels of water intake and other medical illnesses, than the treatment with antipsychotics itself.^229–231

All considered, caution is needed to recognize VTE symptoms early, for example painful edema of the lower limbs, chest pain and dyspnea in patients taking clozapine, especially in those with known risk factors for VTE, like patients over 65, with previous VTE episodes, obesity, MetS, inactivity, lower limb trauma, estrogen treatment, among others.^170,218,225

Conclusion

Despite its potentially life-threatening adverse effects which deserve special attention, clozapine remains the gold standard in the treatment of treatment resistant schizophrenia (TRS) with, to date, inimitable results compared with other available antipsychotics. However, regardless of the evidence, clozapine is still underprescribed or utilized too late and this may be due to, but not limited to, blood monitoring because it is often tedious for the patients,¹²⁹ and the psychiatrists’ fear of severe adverse effects.^232,233

Some psychiatrists do not prescribe clozapine when required as they are anxious about its management and perceive a lack of knowledge and a negative attitude toward this drug.^234,235 Such discomfort with clozapine is a major cause of concern that the patients will pay in terms of a lack of a therapeutic possibility and, therefore, efforts should be made to overcome this.^3,236 This brief review was written not to scare prescribers, but to increase knowledge on the adverse effects of clozapine and to improve their early identification and management. Despite the fear of death of clozapine-treated patients with its possible legal consequences, it is important to emphasize that clozapine treatment may decrease mortality in treated patients by reducing self harm, risk of suicide and attempted suicide.^237,238 Furthermore, Hayes and colleagues^220,239 reported an association between clozapine and reduced risk of mortality from natural causes in a sample of 14,754 individuals with serious mental illness.

Last, but not least, clozapine is the only drug able to restore satisfactory functioning in patients with TRS by improving their lives and self care, even in the long term.^240–243 This should always be kept in mind. Therefore improving our knowledge of clozapine is important to increase the possibility of prescribing it to those in need. Also, improving our knowledge on the adverse effects of clozapine and their management may help to reduce the understandable apprehension of physicians and help them to be more confident when prescribing clozapine.

Footnotes

Acknowledgements

The authors thank Prof. Roberta Polimanti for checking and editing the English language.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of interest statement

No author or immediate family member has financial relationships with commercial organizations that might appear to represent a potential conflict of interest with the material presented.

References

Simeone

Ward

Rotella

et al . An evaluation of variation in published estimates of schizophrenia prevalence from 1990–2013: a systematic literature review. BMC Psychiatry 2015; 15: 193.

Howes

McCutcheon

Agid

et al . Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry 2017; 174: 216–229.

Warnez

Alessi-Severini

. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry 2014; 14: 102.

Kane

Honigfeld

Singer

et al . Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–796.

Remington

Lee

Agid

et al . Clozapine’s critical role in treatment resistant schizophrenia: ensuring both safety and use. Exp Opin Drug Saf 2016; 15: 1193–1203.

Siskind

McCartney

Goldschlager

et al . Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2016; 209: 385–392.

De Berardis

Serroni

Campanella

et al . Safety and efficacy of combined clozapine-azathioprine treatment in a case of resistant schizophrenia associated with Behcet’s disease: a 2-year follow-up. Gen Hosp Psychiatry 2013; 35: 213e9–213e11.

Essali

Al-Haj Haasan

et al . Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2009; 1: CD000059.

Orsolini

Tomasetti

Valchera

et al . An update of safety of clinically used atypical antipsychotics. Exp Opin Drug Saf 2016; 15: 1329–1347.

10.

De Berardis

Serroni

Campanella

et al . Update on the adverse effects of clozapine: focus on myocarditis. Curr Drug Saf 2012; 7: 55–62.

11.

Solmi

Murru

Pacchiarotti

et al . Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag 2017; 13: 757–777.

12.

Wicinski

Weclewicz

. Clozapine-induced agranulocytosis/granulocytopenia: mechanisms and monitoring. Curr Opin Hematol 2018; 25: 22–28.

13.

Cadeddu

Deidda

Stochino

et al . Clozapine toxicity due to a multiple drug interaction: a case report. J Med Case Rep 2015; 9: 77.

14.

Buur-Rasmussen

Brosen

. Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. Eur Neuropsychopharmacol 1999; 9: 453–459.

15.

Fang

Coutts

McKenna

et al . Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedeberg’s Arch Pharmacol 1998; 358: 592–599.

16.

Eiermann

Engel

Johansson

et al . The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997; 44: 439–446.

17.

Olesen

Linnet

. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 2001; 41: 823–832.

18.

Chetty

Murray

. CYP-mediated clozapine interactions: how predictable are they? Curr Drug Metab 2007; 8: 307–313.

19.

Lowe

Ackman

. Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment. Ann Pharmacother 2010; 44: 727–732.

20.

Bastiampillai

Allison

Gupta

. The clinical utility of therapeutic drug monitoring for clozapine. Aust N Z J Psychiatry 2017; 51: 295–296.

21.

Lopez

Kane

. Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: a review of the literature. Schizophr Res 2013; 147: 368–374.

22.

Iglesias Garcia

Iglesias Alonso

Bobes

. Concentrations in plasma clozapine levels in schizophrenic and schizoaffective patients. Rev Psiquiatr Salud Ment 2017; 10: 192–196.

23.

Spina

Avenoso

Facciola

et al . Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology 2000; 148: 83–89.

24.

Iasevoli

Giordano

Balletta

et al . Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones. Prog Neuropsychopharmacol Biol Psychiatry 2016; 65: 34–48.

25.

Ebisch

Salone

Ferri

et al . Out of touch with reality? Social perception in first-episode schizophrenia. Soc Cogn Affect Neurosci 2013; 8: 394–403.

26.

Marasco

De Berardis

Serroni

et al . Alexithymia and suicide risk among patients with schizophrenia: preliminary findings of a cross-sectional study. Riv Psichiatr 2011; 46: 31–37.

27.

Raja

. Clozapine safety, 40 years later. Curr Drug Saf 2014; 9: 163–195.

28.

Iqbal

Rahman

Husain

et al . Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry 2003; 15: 33–48.

29.

Bak

. Monitoring clozapine adverse effects calls for the integration of protocol and good clinical practice. J Clin Psychiatry 2012; 73: 1313–1314.

30.

Miyamoto

Jarskog

Fleischhacker

. Schizophrenia: when clozapine fails. Curr Opin Psychiatry 2015; 28: 243–248.

31.

Meltzer

Bastani

Ramirez

et al . Clozapine: new research on efficacy and mechanism of action. Eur Arch Psychiatry Neurol Sci 1989; 238: 332–339.

32.

Bunney

. Clozapine: a hypothesised mechanism for its unique clinical profile. Br J Psychiatry Suppl 1992: 17–21.

33.

Seeman

. Clozapine, a fast-off-D2 antipsychotic. ACS Chem Neurosci 2014; 5: 24–29.

34.

Vauquelin

Bostoen

Vanderheyden

et al . Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism. Naunyn Schmiedeberg’s Arch Pharmacol 2012; 385: 337–372.

35.

Stahl

. Stahl’s essential psychopharmacology: prescriber’s guide. 5th ed. New York, NY: Cambridge University Press, 2014, p.xvi, 802.

36.

Bishara

Taylor

. Adverse effects of clozapine in older patients: epidemiology, prevention and management. Drugs Aging 2014; 31: 11–20.

37.

Sporn

Vermani

Greenstein

et al . Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry 2007; 46: 1349–1356.

38.

Grover

Hazari

Chakrabarti

et al . Metabolic disturbances, side effect profile and effectiveness of clozapine in adolescents. Indian J Psychol Med 2016; 38: 224–233.

39.

Roge

Moller

Andersen

et al . Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr Res 2012; 140: 204–213.

40.

Pollmacher

Schuld

Kraus

et al . On the clinical relevance of clozapine-triggered release of cytokines and soluble cytokine-receptors. Fortschr Neurol Psychiatr 2001; 69(Suppl. 2): S65–S74.

41.

De Berardis

Campanella

Gambi

et al . The role of C-reactive protein in mood disorders. Int J Immunopathol Pharmacol 2006; 19: 721–725.

42.

Maes

Bosmans

Kenis

et al . In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 1997; 26: 221–225.

43.

Kracmarova

Pohanka

. The impact of clozapine on regulation of inflammation in murine macrophage cells. Neuro Endocrinol Lett 2014; 35(Suppl. 2): 175–179.

44.

Klemettila

Kampman

Seppala

et al . Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine. Psychiatry Res 2014; 218: 277–283.

45.

Heiser

Enning

Krieg

et al . Effects of haloperidol, clozapine and olanzapine on the survival of human neuronal and immune cells in vitro. J Psychopharmacol 2007; 21: 851–856.

46.

Hinze-Selch

Becker

Stein

et al . Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacology 1998; 19: 114–122.

47.

Capannolo

Fasciani

Romeo

et al . The atypical antipsychotic clozapine selectively inhibits interleukin 8 (IL-8)-induced neutrophil chemotaxis. Eur Neuropsychopharmacol 2015; 25: 413–424.

48.

O’Connell

Thakore

Dev

. Pro-inflammatory cytokine levels are raised in female schizophrenia patients treated with clozapine. Schizophr Res 2014; 156: 1–8.

49.

Ajami

Abedian

Hamzeh Hosseini

et al . Serum TNF-α, IL-10 and IL-2 in schizophrenic patients before and after treatment with risperidone and clozapine. Iran J Immunol 2014; 11: 200–209.

50.

Watkins

Andrews

. Clinical studies of neuroinflammatory mechanisms in schizophrenia. Schizophr Res 2016; 176: 14–22.

51.

Muller

. Immunology of schizophrenia. Neuroimmunomodulation 2014; 21: 109–116.

52.

Guzelcan

Scholte

. Clozapine-induced agranulocytosis: genetic risk factors and an immunologic explanatory model. Tijdschr Psychiatr 2006; 48: 295–302.

53.

Testani

Jr.

Clozapine-induced orthostatic hypotension treated with fludrocortisone. J Clin Psychiatry 1994; 55: 497–498.

54.

Hummer

Kemmler

Kurz

et al . Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. Am J Psychiatry 1999; 156: 631–633.

55.

Mullen

Brar

Vagnucci

et al . Frequency of sexual dysfunctions in patients with schizophrenia on haloperidol, clozapine or risperidone. Schizophr Res 2001; 48: 155–158.

56.

Perdigues

Quecuti

Mane

et al . An observational study of clozapine induced sedation and its pharmacological management. Eur Neuropsychopharmacol 2016; 26: 156–161.

57.

Sauras

Ramos

Mann

et al . A study of clozapine-induced sedation. Actas Esp Psiquiatr 2016; 44: 244–252.

58.

Gareri

De Fazio

Russo

et al . The safety of clozapine in the elderly. Exp Opin Drug Saf 2008; 7: 525–538.

59.

Sethy

Ellerbrock

. Comparative dopaminergic and muscarinic antagonist activity of clozapine and haloperidol. Life Sci 1996; 58: 585–590.

60.

Citrome

McEvoy

Saklad

. Guide to the management of clozapine-related tolerability and safety concerns. Clin Schizophr Relat Psychoses 2016; 10: 163–177.

61.

Saenger

Finch

Francois

. Aspiration pneumonia due to clozapine-induced sialorrhea. Clin Schizophr Relat Psychoses 2016; 9: 170–172.

62.

Hinkes

Quesada

Currier

et al . Aspiration pneumonia possibly secondary to clozapine-induced sialorrhea. J Clin Psychopharmacol 1996; 16: 462–463.

63.

Matos Santana

Capurso

Ranganathan

et al . Sublingual atropine in the treatment of clozapine-induced sialorrhea. Schizophr Res 2017; 182: 144–145.

64.

Man

Colen-de Koning

Schulte

et al . The effect of glycopyrrolate on nocturnal sialorrhea in patients using clozapine: a randomized, crossover, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2017; 37: 155–161.

65.

Sinha

Simlai

Praharaj

. Very low dose amitriptyline for clozapine-associated sialorrhea. Curr Drug Saf 2016; 11: 262–263.

66.

Kulkarni

. Low-dose amisulpride for debilitating clozapine-induced sialorrhea: case series and review of literature. Indian J Psychol Med 2015; 37: 446–448.

67.

Bird

Smith

Walton

. Current treatment strategies for clozapine-induced sialorrhea. Ann Pharmacother 2011; 45: 667–675.

68.

Kumlien

Lundberg

. Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database. Seizure 2010; 19: 69–73.

69.

Pisani

Oteri

Costa

et al . Effects of psychotropic drugs on seizure threshold. Drug Saf 2002; 25: 91–110.

70.

Williams

Park

. Seizure associated with clozapine: incidence, etiology, and management. CNS Drugs 2015; 29: 101–111.

71.

Kikuchi

Sato

Ataka

et al . Clozapine-induced seizures, electroencephalography abnormalities, and clinical responses in Japanese patients with schizophrenia. Neuropsychiatr Dis Treat 2014; 10: 1973–1978.

72.

Dumortier

Mahe

Pons

et al . Clonic seizure associated with high clozapine plasma level. J Neuropsychiatry Clin Neurosci 2001; 13: 302–303.

73.

Wang

Yeh

et al . Comparative risk of seizure with use of first- and second-generation antipsychotics in patients with schizophrenia and mood disorders. J Clin Psychiatry 2016; 77: e573–e579.

74.

Balen

Procyshyn

. Valproic acid for seizure prophylaxis during clozapine therapy: where’s the evidence? Int J Psychiatry Clin Pract 1999; 3: 249–251.

75.

Foster

Olajide

. A case of clozapine-induced tonic-clonic seizures managed with valproate: implications for clinical care. J Psychopharmacol 2005; 19: 93–96.

76.

Varma

Bishara

Besag

et al . Clozapine-related EEG changes and seizures: dose and plasma-level relationships. Ther Adv Psychopharmacol 2011; 1: 47–66.

77.

Henderson

Cagliero

Gray

et al . Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157: 975–981.

78.

Smith

Hopkins

Peveler

et al . First-v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2008; 192: 406–411.

79.

Choong

Bondolfi

Etter

et al . Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population. J Psychiatr Res 2012; 46: 540–548.

80.

Hirsch

Yang

Bresee

et al . Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf 2017; 40: 771–781.

81.

Citrome

McEvoy

Saklad

. A guide to the management of clozapine-related tolerability and safety concerns. Clin Schizophr Relat Psychoses 2016; 10:163-177.

82.

Hong

Lin

et al . Genetic variant of the histamine-1 receptor (glu349asp) and body weight change during clozapine treatment. Psychiatr Genet 2002; 12: 169–171.

83.

Humbert-Claude

Davenas

Gbahou

et al . Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo. Psychopharmacology 2012; 220: 225–241.

84.

Meltzer

. An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994; 55(Suppl. B): 47–52.

85.

Rojo

Gaspar

Silva

et al . Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. Pharmacol Res 2015; 101: 74–85.

86.

Vancampfort

Stubbs

Mitchell

et al . Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 2015; 14: 339–347.

87.

Allison

Mentore

Heo

et al . Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–1696.

88.

Whitney

Procyshyn

Fredrikson

et al . Treatment of clozapine-associated weight gain: a systematic review. Eur J Clin Pharmacol 2015; 71: 389–401.

89.

Henderson

Daley

Kunkel

et al . Clozapine and hypertension: a chart review of 82 patients. J Clin Psychiatry 2004; 65: 686–689.

90.

Lund

Perry

Brooks

et al . Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 2001; 58: 1172–1176.

91.

Dursun

Szemis

Andrews

et al . The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. J Psychiatry Neurosci 1999; 24: 453–455.

92.

Kelly

Sheitman

Hamer

et al . A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses. J Clin Psychopharmacol 2014; 34: 441–445.

93.

Lafayette

Pirl

Henderson

. Low-dose clozapine and diabetic ketoacidosis. Psychosomatics 2003; 44: 249–252.

94.

Pierides

. Clozapine monotherapy and ketoacidosis. Br J Psychiatry 1997; 171: 90–91.

95.

Cohen

Bogers

van Dijk

et al . Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry 2012; 73: 1307–1312.

96.

Nihalani

Lamberti

et al . Diabetic ketoacidosis among patients receiving clozapine: a case series and review of socio-demographic risk factors. Ann Clin Psychiatry 2007; 19: 105–112.

97.

Cooper

Reynolds

; With Expert Co-authorset al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol 2016; 30: 717–748.

98.

Dayabandara

Hanwella

Ratnatunga

et al . Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat 2017; 13: 2231–2241.

99.

Tso

Kumar

Jayasooriya

et al . Metabolic monitoring and management among clozapine users. Australas Psychiatry 2017; 25: 48–52.

100.

Hayes

Gibler

. Clozapine-induced constipation. Am J Psychiatry 1995; 152: 298.

101.

Drew

Herdson

. Clozapine and constipation: a serious issue. Aust N Z J Psychiatry 1997; 31: 149–150.

102.

Baptista

Carrizo

Fernandez

et al . Colonic transit diagnostic test shows significant gastrointestinal hypomotility in clozapine-treated patients in comparison with subjects treated with other antipsychotics. Schizophr Res 2015; 166: 207–211.

103.

Palmer

McLean

Ellis

et al . Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry 2008; 69: 759–768.

104.

Every-Palmer

Lentle

Reynolds

et al . Spatiotemporal mapping techniques show clozapine impairs neurogenic and myogenic patterns of activity in the colon of the rabbit in a dose-dependent manner. Front Pharmacol 2017; 8: 209.

105.

de Alvarenga

KAF

Sacramento

Rosa

et al . Effects of antipsychotics on intestinal motility in zebrafish larvae. Neurogastroenterol Motil 2017; 29.

106.

Every-Palmer

Nowitz

Stanley

et al . Clozapine-treated patients have marked gastrointestinal hypomotility, the probable basis of life-threatening gastrointestinal complications: a cross sectional study. EBioMedicine 2016; 5: 125–134.

107.

Shirazi

Stubbs

Gomez

et al . Prevalence and predictors of clozapine-associated constipation: a systematic review and meta-analysis. Int J Mol Sci 2016; 17.

108.

Every-Palmer

Ellis

. Clozapine-induced gastrointestinal hypomotility: a 22-year bi-national pharmacovigilance study of serious or fatal ‘Slow Gut’ reactions, and comparison with international drug safety advice. CNS Drugs 2017; 31: 699–709.

109.

Flanagan

Ball

. Gastrointestinal hypomotility: an under-recognised life-threatening adverse effect of clozapine. Forensic Sci Int 2011; 206: e31–e36.

110.

Nielsen

Meyer

. Risk factors for ileus in patients with schizophrenia. Schizophr Bull 2012; 38: 592–598.

111.

Baptista

. A fatal case of ischemic colitis during clozapine administration. Rev Bras Psiquiatr 2014; 36: 358.

112.

Rodriguez-Sosa

Lazaro-Archilla

Trujillo-Cubas

. Apropos of a case: relationship of ischemic colitis with clozapine. Actas Esp Psiquiatr 2014; 42: 325–326.

113.

Shah

Anderson

. Clozapine-induced ischaemic colitis. BMJ Case Rep 2013; 2013.

114.

Galappathie

Khan

. Clozapine-associated pneumonia and respiratory arrest secondary to severe constipation. Med Sci Law 2014; 54: 105–109.

115.

De Hert

Hudyana

Dockx

et al . Second-generation antipsychotics and constipation: a review of the literature. Eur Psychiatry 2011; 26: 34–44.

116.

John

Chengappa

Baker

et al . Assessment of changes in both weight and frequency of use of medications for the treatment of gastrointestinal symptoms among clozapine-treated patients. Ann Clin Psychiatry 1995; 7: 119–125.

117.

Legge

. Examining treatment response and adverse effects of clozapine. Doctoral Dissertation, Cardiff University, 2015.

118.

Every-Palmer

Ellis

Nowitz

et al . The Porirua protocol in the treatment of clozapine-induced gastrointestinal hypomotility and constipation: a pre- and post-treatment study. CNS Drugs 2017; 31: 75–85.

119.

Chukhin

Takala

Hakko

et al . In a randomized placebo-controlled add-on study orlistat significantly reduced clozapine-induced constipation. Int Clin Psychopharmacol 2013; 28: 67–70.

120.

Werner

Covenas

. Safety of antipsychotic drugs: focus on therapeutic and adverse effects. Exp Opin Drug Saf 2014; 13: 1031–1042.

121.

Wang

Zhang

. Case report on clozapine-associated neuroleptic malignant syndrome. Shanghai Arch Psychiatry 2012; 24: 116–117.

122.

Leonardo

Juliana

Fernando

. Atypical neuroleptic malignant syndrome associated with use of clozapine. Case Rep Emerg Med 2017; 2017: 2174379.

123.

Mesquita

Siva

. Fatal neuroleptic malignant syndrome induced by clozapine in Parkinson’s psychosis. J Neuropsychiatry Clin Neurosci 2014; 26: E34.

124.

Szota

Oglodek

Araszkiewicz

. Fever development in neuroleptic malignant syndrome during treatment with olanzapine and clozapine. Pharmacol Rep 2013; 65: 279–287.

125.

Cherry

Siskind

Spivak

et al . Fever, confusion, acute kidney injury: is this atypical neuroleptic malignant syndrome following polypharmacy with clozapine and risperidone? Australas Psychiatry 2016; 24: 602–603.

126.

Bonnet

Taazimi

Montag

et al . Severe acute pancreatitis, neuroleptic malignant syndrome and grand mal seizures associated with elevated amisulpride and low clozapine serum levels. Psychiatr Danub 2015; 27: 424–425.

127.

Demler

Morabito

Meyer

et al . Maximizing clozapine utilization while minimizing blood dyscrasias: evaluation of patient demographics and severity of events. Int Clin Psychopharmacol 2016; 31: 76–83.

128.

Fabrazzo

Prisco

Sampogna

et al . Clozapine versus other antipsychotics during the first 18 weeks of treatment: a retrospective study on risk factor increase of blood dyscrasias. Psychiatry Res 2017; 256: 275–282.

129.

Mohapatra

. New food and drug administration recommendations for clozapine prescribing and monitoring requirements. Indian J Psychol Med 2016; 38: 488–489.

130.

Hippius

. The history of clozapine. Psychopharmacology 1989; 99: S3–S5.

131.

Atkin

Kendall

Gould

et al . Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996; 169: 483–488.

132.

Ingimarsson

MacCabe

Haraldsson

et al . Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland. BMC Psychiatry 2016; 16: 441.

133.

Ratanajamit

Musakopas

Vasiknanonte

et al . Incidence and risk for neutropenia/agranulocytosis among clozapine users: a retrospective cohort study. Int J Psychiatry Clin Pract 2010; 14: 109–115.

134.

Rajagopal

. Clozapine, agranulocytosis, and benign ethnic neutropenia. Postgrad Med J 2005; 81: 545–546.

135.

Nooijen

Carvalho

Flanagan

. Haematological toxicity of clozapine and some other drugs used in psychiatry. Hum Psychopharmacol 2011; 26: 112–119.

136.

Singh

Grover

Malhotra

et al . Late onset agranulocytosis with clozapine associated with HLA DR4 responding to treatment with granulocyte colony-stimulating factor: a case report and review of literature. Clin Psychopharmacol Neurosci 2016; 14: 212–217.

137.

Velayudhan

Kakkan

. Late onset clozapine induced agranulocytosis. Indian J Psychol Med 2014; 36: 425–427.

138.

Demler

Trigoboff

. Are clozapine blood dyscrasias associated with concomitant medications? Innov Clin Neurosci 2011; 8: 35–41.

139.

de With

SAJ

Pulit

Staal

et al . More than 25 years of genetic studies of clozapine-induced agranulocytosis. Pharmacogenomics J 2017; 17: 304–311.

140.

Opgen-Rhein

Dettling

. Clozapine-induced agranulocytosis and its genetic determinants. Pharmacogenomics 2008; 9: 1101–1111.

141.

Lahdelma

Appelberg

. Clozapine-induced agranulocytosis in Finland, 1982–2007: long-term monitoring of patients is still warranted. J Clin Psychiatry 2012; 73: 837–842.

142.

Dettling

Cascorbi

Opgen-Rhein

et al . Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. Pharmacogenomics J 2007; 7: 325–332.

143.

Alvir

Lieberman

Safferman

et al . Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329: 162–167.

144.

Liu

Uetrecht

. Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. J Pharmacol Exp Ther 1995; 275: 1476–1483.

145.

Regen

Herzog

Hahn

et al . Clozapine-induced agranulocytosis: evidence for an immune-mediated mechanism from a patient-specific in-vitro approach. Toxicol Appl Pharmacol 2017; 316: 10–16.

146.

Uetrecht

. Metabolism of clozapine by neutrophils. Possible implications for clozapine-induced agranulocytosis. Drug Saf 1992; 7(Suppl. 1): 51–56.

147.

Kennar

Uetrecht

. Effect of clozapine and olanzapine on neutrophil kinetics: implications for drug-induced agranulocytosis. Chem Res Toxicol 2014; 27: 1104–1108.

148.

Williams

Pirmohamed

Naisbitt

et al . Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Mol Pharmacol 2000; 58: 207–216.

149.

Sultan

Olfson

Correll

et al . Evaluating the effect of the changes in FDA guidelines for clozapine monitoring. J Clin Psychiatry 2017; 78: e933–e939.

150.

Mouaffak

Foulon

Smail

et al . Clozapine: latest FDA recommendations and our practice. L’Encephale 2016; 42: 600–601.

151.

Bastiampillai

Gupta

Allison

. FDA changes clozapine monitoring guidelines: implications for worldwide practice. Asian J Psychiatr 2016; 21: 19–20.

152.

Leiderman

. Risk management of drug products and the U.S. Food and Drug Administration: evolution and context. Drug Alcohol Depend 2009; 105(Suppl. 1): S9–S13.

153.

Lally

Malik

Whiskey

et al . Clozapine-associated agranulocytosis treatment with granulocyte colony-stimulating factor/granulocyte-macrophage colony-stimulating factor: a systematic review. J Clin Psychopharmacol 2017; 37: 441–446.

154.

Hazewinkel

Bogers

Giltay

. Add-on filgrastim during clozapine rechallenge unsuccessful in preventing agranulocytosis. Gen Hosp Psychiatry 2013; 35: 576e11–576e12.

155.

Lertxundi

Sanchez

Hernandez

et al . A case of agranulocytosis secondary to rechallenge with clozapine following severe neutropenia during previous therapy. J Clin Psychiatry 2011; 72: 1659.

156.

Safferman

Lieberman

Alvir

et al . Rechallenge in clozapine-induced agranulocytosis. Lancet 1992; 339: 1296–1297.

157.

McKnight

Guirgis

Votolato

. Clozapine rechallenge after excluding the high-risk clozapine-induced agranulocytosis genotype of HLA-DQB1 6672G>C. Am J Psychiatry 2011; 168: 1120.

158.

Joffe

Eskelinen

Sailas

. Add-on filgrastim during clozapine rechallenge in patients with a history of clozapine-related granulocytopenia/agranulocytosis. Am J Psychiatry 2009; 166: 236.

159.

Dunk

Annan

Andrews

. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 2006; 188: 255–263.

160.

Prokopez

Armesto

Gil Aguer

et al . Clozapine rechallenge after neutropenia or leucopenia. J Clin Psychopharmacol 2016; 36: 377–380.

161.

Kang

Kwon

Ahn

et al . Electrocardiographic abnormalities in patients treated with clozapine. J Clin Psychiatry 2000; 61: 441–446.

162.

Dhillon

Bastiampillai

Tee

et al . Clozapine and associated QTc prolongation. Aust N Z J Psychiatry 2011; 45: 1098–1099.

163.

Olsen

Kroken

Bjorhovde

et al . Influence of different second generation antipsychotics on the QTc interval: a pragmatic study. World J Psychiatry 2016; 6: 442–448.

164.

Warner

Hoffmann

. Investigation of the potential of clozapine to cause torsade de pointes. Adverse Drug React Toxicol Rev 2002; 21: 189–203.

165.

Carra

Crocamo

Bartoli

et al . First-generation antipsychotics and QTc: any role for mediating variables? Hum Psychopharmacol 2016; 31: 313–318.

166.

Hasnain

Vieweg

. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs 2014; 28: 887–920.

167.

Acciavatti

Lupi

Santacroce

et al . Novel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders: a multicenter-observational study. Hum Psychopharmacol 2017; 32.

168.

Hazell

Raschi

De Ponti

et al . Evidence for the hERG liability of antihistamines, antipsychotics, and anti-infective agents: a systematic literature review from the ARITMO project. J Clin Pharmacol 2017; 57: 558–572.

169.

Lee

Kim

et al . Blockade of HERG human K+ channels and IKr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine. Br J Pharmacol 2006; 148: 499–509.

170.

Ronaldson

. Cardiovascular disease in clozapine-treated patients: evidence, mechanisms and management. CNS Drugs 2017; 31: 777–795.

171.

Agelink

Majewski

Wurthmann

et al . Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol 2001; 21: 8–13.

172.

Sala

Vicentini

Brambilla

et al . QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry 2005; 4: 1.

173.

Alexopoulos

Streim

Carpenter

et al .; Expert Consensus Panel for Using Antipsychotic Drugs in Older P. Using antipsychotic agents in older patients. J Clin Psychiatry 2004; 65(Suppl. 2): 5–99; discussion 100–102; quiz 103–104.

174.

Takeuchi

Suzuki

Remington

et al . Antipsychotic polypharmacy and corrected QT interval: a systematic review. Can J Psychiatry 2015; 60: 215–222.

175.

Piersanti

Capannolo

Turchetti

et al . Increase in mortality rate in patients with dementia treated with atypical antipsychotics: a cohort study in outpatients in Central Italy. Riv Psichiatr 2014; 49: 34–40.

176.

Rautaharju

Surawicz

Gettes

et al . AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. Circulation 2009; 119: e241–e250.

177.

Kim

White

Barr

et al . Clozapine, elevated heart rate and QTc prolongation. J Psychiatry Neurosci 2018; 43: 71–72.

178.

Alawami

Wasywich

Cicovic

et al . A systematic review of clozapine induced cardiomyopathy. Int J Cardiol 2014; 176: 315–320.

179.

Longhi

Heres

. Clozapine-induced, dilated cardiomyopathy: a case report. BMC Res Notes 2017; 10: 338.

180.

Finsterer

Stollberger

. Noncompaction and dilated cardiomyopathy in a patient with schizophrenia. Case Rep Cardiol 2016; 2016: 7384264.

181.

Makhoul

Hochberg

Rispler

et al . Dilated cardiomyopathy: an unusual complication of clozapine therapy. Nat Clin Pract Cardiovasc Med 2008; 5: 566–570.

182.

Ronaldson

Fitzgerald

McNeil

. Clozapine-induced myocarditis, a widely overlooked adverse reaction. Acta Psychiatr Scand 2015; 132: 231–240.

183.

Ronaldson

Fitzgerald

Taylor

et al . Clozapine-induced myocarditis and baseline echocardiography. Aust N Z J Psychiatry 2012; 46: 1006–1007.

184.

Ronaldson

Fitzgerald

Taylor

et al . Clinical course and analysis of ten fatal cases of clozapine-induced myocarditis and comparison with 66 surviving cases. Schizophr Res 2011; 128: 161–165.

185.

Ronaldson

Fitzgerald

Taylor

et al . A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry 2011; 45: 458–465.

186.

Haas

Hill

Krum

et al . Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993–2003. Drug Saf 2007; 30: 47–57.

187.

Molina Martin de Nicolas

Parra Fuertes

Gomez Mariscal

et al . Clozapine-associated myocarditis. Med Clin 2015; 145: e19–e20.

188.

Rostagno

Domenichetti

Pastorelli

et al . Clozapine associated cardiomyopathy: a cluster of 3 cases. Intern Emerg Med 2011; 6: 281–283.

189.

Power

Williams

Shymko

. The difficulties of diagnosing clozapine myocarditis: damned if you do, damned if you don’t. Australas Psychiatry 2012; 20: 165–166.

190.

Goodison

Siskind

Harcourt-Rigg

et al . Clarifying the diagnosis of myocarditis in a patient on clozapine. Australas Psychiatry 2015; 23: 311–313.

191.

Cook

Ferguson

Cotes

et al . Clozapine-induced myocarditis: prevention and considerations in rechallenge. Psychosomatics 2015; 56: 685–690.

192.

Hatton

Bhat

Gandhi

. Clozapine-induced myocarditis: recognizing a potentially fatal adverse reaction. Tex Heart Inst J 2015; 42: 155–157.

193.

Khan

Ashraf

Baker

et al . Clozapine and incidence of myocarditis and sudden death: long term Australian experience. Int J Cardiol 2017; 238: 136–139.

194.

Youssef

Narayanan

Gill

. Incidence and risk factors for clozapine-induced myocarditis and cardiomyopathy at a regional mental health service in Australia. Australas Psychiatry 2016; 24: 176–180.

195.

Chopra

de Leon

. Clozapine-induced myocarditis may be associated with rapid titration: a case report verified with autopsy. Int J Psychiatry Med 2016; 51: 104–115.

196.

Coulter

Bate

Meyboom

et al . Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 2001; 322: 1207–1209.

197.

Ronaldson

Fitzgerald

Taylor

et al . Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study. Schizophr Res 2012; 141: 173–178.

198.

Goldsmith

Cotes

. An unmet need: a clozapine-induced myocarditis screening protocol. Prim Care Companion CNS Disord 2017; 19.

199.

Caforio

Pankuweit

Arbustini

et al . Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34: 2636–2648, 2648a–2648d.

200.

Howlett

McKelvie

Arnold

et al . Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials. Can J Cardiol 2009; 25: 85–105.

201.

Pieroni

Cavallaro

Chimenti

et al . Clozapine-induced hypersensitivity myocarditis. Chest 2004; 126: 1703–1705.

202.

Hagg

Spigset

Bate

et al . Myocarditis related to clozapine treatment. J Clin Psychopharmacol 2001; 21: 382–388.

203.

Ronaldson

Fitzgerald

Taylor

et al . Observations from 8 cases of clozapine rechallenge after development of myocarditis. J Clin Psychiatry 2012; 73: 252–254.

204.

Reinders

Parsonage

Lange

et al . Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust N Z J Psychiatry 2004; 38: 915–922.

205.

Ittasakul

Archer

Kezman

et al . Rapid rechallenge with clozapine following pronounced myocarditis in a treatment-resistant schizophrenia patient. Clin Schizophr Relat Psychoses 2016; 10: 120–122.

206.

Chow

Feijo

Trieu

et al . Successful rechallenge of clozapine therapy following previous clozapine-induced myocarditis confirmed on cardiac MRI. J Child Adolesc Psychopharmacol 2014; 24: 99–101.

207.

Ittasakul

Archer

Kezman

et al . Rapid re-challenge with clozapine following pronounced myocarditis in a treatment-resistance schizophrenia patient. Clin Schizophr Relat Psychoses 2013: 1–11.

208.

Paul

Basavaraju

Narayanaswamy

et al . Clozapine-induced pericarditis: an overlooked adverse effect. Clin Schizophr Relat Psychoses 2014; 8: 133–134.

209.

Imon Paul

Basavaraju

Narayanaswamy

et al . Clozapine induced pericarditis. Clin Schizophr Relat Psychoses 2014: 1–6.

210.

De Berardis

Campanella

Serroni

et al . Clozapine-related pericarditis during titration phase in a patient with resistant schizophrenia and concomitant valproate treatment: a case report. J Clin Psychopharmacol 2014; 34: 649–651.

211.

Markovic

Momcilov-Popin

Mitrovic

et al . Clozapine-induced pericarditis. Afr J Psychiatry 2011; 14: 236–238.

212.

Rathore

Masani

Callaghan

. Clozapine-induced effuso-constrictive pericarditis. Case report and review of the literature. Cardiology 2007; 108: 183–185.

213.

Crews

Dhillon

MacCabe

. Clozapine rechallenge following clozapine-induced pericarditis. J Clin Psychiatry 2010; 71: 959–961.

214.

Manu

Sarpal

Muir

et al . When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res 2012; 134: 180–186.

215.

Parker

Coupland

Hippisley-Cox

. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ 2010; 341: c4245.

216.

Stroup

Gerhard

Crystal

et al . Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry 2016; 173: 166–173.

217.

Gami

Mishra

Sedlak

. Pulmonary embolism and clozapine use: a case report and literature review. Psychosomatics 2017; 58: 203–208.

218.

Jonsson

Spigset

Hagg

. Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and management. CNS Drugs 2012; 26: 649–662.

219.

Liperoti

Gambassi

. Antipsychotics and the risk of venous thromboembolism. BMJ 2010; 341: c4216.

220.

Walker

Lanza

Arellano

et al . Mortality in current and former users of clozapine. Epidemiology 1997; 8: 671–677.

221.

Axelsson

Hagg

Eriksson

et al . In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation. Clin Exp Pharmacol Physiol 2007; 34: 775–780.

222.

Voulgari

Giannas

Paterakis

et al . Clozapine-induced late agranulocytosis and severe neutropenia complicated with Streptococcus pneumonia, venous thromboembolism, and allergic vasculitis in treatment-resistant female psychosis. Case Rep Med 2015; 2015: 703218.

223.

Hagg

Bate

Stahl

et al . Associations between venous thromboembolism and antipsychotics. A study of the WHO database of adverse drug reactions. Drug Saf 2008; 31: 685–694.

224.

Jonsson

Horvath-Puho

Hagg

et al . Antipsychotics and risk of venous thromboembolism: a population-based case-control study. Clin Epidemiol 2009; 1: 19–26.

225.

Letmaier

Grohmann

Kren

et al . Venous thromboembolism during treatment with antipsychotics: results of a drug surveillance programme. World J Biol Psychiatry 2017: 1–12.

226.

Wang

Liou

Huang

et al . Use of antipsychotics and risk of venous thromboembolism in postmenopausal women. A population-based nested case-control study. Thromb Haemost 2016; 115: 1209–1219.

227.

Chandele

Cholera

Kale

et al . Theoretical and practical issues related to the management of severe and refractory psychotic illness complicated by pulmonary embolism. Indian J Psychiatry 2015; 57: 414–418.

228.

Allenet

Schmidlin

Genty

et al . Antipsychotic drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf 2012; 21: 42–48.

229.

Paciullo

. Evaluating the association between clozapine and venous thromboembolism. Am J Health Syst Pharm 2008; 65: 1825–1829.

230.

Stein

Matta

Goldman

. Obesity and pulmonary embolism: the mounting evidence of risk and the mortality paradox. Thromb Res 2011; 128: 518–523.

231.

Chapelle

Quenet

Delavenne

et al . Antipsychotics: a real or confounding risk factor for venous thromboembolism? Pharmacopsychiatry 2013; 46: 36–37.

232.

Niehues

Balan

Pra

et al . Trends in the prescription of clozapine in a psychiatric hospital: a 5-year observational study. Trends Psychiatry Psychother 2017; 39: 158–164.

233.

Alessi-Severini

Le Dorze

Nguyen

et al . Clozapine prescribing in a Canadian outpatient population. PLoS One 2013; 8: e83539.

234.

Grover

Balachander

Chakarabarti

et al . Prescription practices and attitude of psychiatrists towards clozapine: a survey of psychiatrists from India. Asian J Psychiatr 2015; 18: 57–65.

235.

Tungaraza

Farooq

. Clozapine prescribing in the UK: views and experience of consultant psychiatrists. Ther Adv Psychopharmacol 2015; 5: 88–96.

236.

Carruthers

Radigan

Erlich

et al . An initiative to improve clozapine prescribing in New York State. Psychiatr Serv 2016; 67: 369–371.

237.

Wimberley

MacCabe

Laursen

et al . Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry 2017; 174: 990–998.

238.

Ringback Weitoft

Berglund

et al . Mortality, attempted suicide, re-hospitalisation and prescription refill for clozapine and other antipsychotics in Sweden-a register-based study. Pharmacoepidemiol Drug Saf 2014; 23: 290–298.

239.

Hayes

Downs

Chang

et al . The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders. Schizophr Bull 2015; 41: 644–655.

240.

Bender

Dittmann-Balcar

Schall

et al . Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine. Int J Neuropsychopharmacol 2006; 9: 135–145.

241.

McGurk

. The effects of clozapine on cognitive functioning in schizophrenia. J Clin Psychiatry 1999; 60(Suppl. 12): 24–29.

242.

Fujii

Ahmed

Jokumsen

et al . The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. J Neuropsychiatry Clin Neurosci 1997; 9: 240–245.

243.

Grace

Bellus

Raulin

et al . Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Psychiatr Serv 1996; 47: 41–45.

Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine

Abstract

Keywords

Introduction

Materials and methods of the review

Clozapine mechanism of action and relationships with adverse effects

Common adverse effects

Seizures

Weight gain and the risk of MetS

Gastrointestinal hypomotility and constipation

Uncommon adverse effects

Blood dyscrasias and agranulocytosis/granulocytopenia

Uncommon adverse effects

QT prolongation

Clozapine-induced cardiomyopathy, myocarditis and pericarditis

Venous thromboembolism

Conclusion

Footnotes

Acknowledgements

Funding

Conflict of interest statement

References